TMO · Q4 2025 Earnings

Bullish

Thermo Fisher Scientific

Reported January 29, 2026

30-second summary

Q4 organic revenue growth came in at 3% (reported +7% to $12.21B) with adjusted EPS of $6.57, and management initiated FY2026 guidance of $46.3–$47.2B revenue (+4–6% reported, +3–4% organic) and $24.22–$24.80 adjusted EPS (+6–8%) — the first time the 2026–2027 3–6% framework has been dollar-quantified, and the organic midpoint lands in the lower half of that band. FY2025 revenue ($44.56B) and adjusted EPS ($22.87) both finished slightly above the high end of the prior guide, while adjusted operating margin came in at 22.7%, meeting the low end of the raised 22.7–22.8% range. The FY2026 Clario announcement adds another 20–25c of EPS upside not in the base guide. The cautious posture of Q2/Q3 has been replaced with an explicit "position of strength" frame backed by execution.

Headline numbers

EPS

Q4 FY2025

$6.57

Revenue

Q4 FY2025

$12.21B

+7.0% YoY

Gross margin

Q4 FY2025

41.5%

Free cash flow

Q4 FY2025

$3.02B

Operating margin

Q4 FY2025

18.5%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$12.21B	+7.0%	$11.12B	+9.8%
EPS	$6.57	—	$5.79	+13.5%
Gross margin	41.5%	—	41.8%	-30bps
Operating margin	18.5%	—	17.4%	+110bps
Free cash flow	$3.02B	—	$1.84B	+64.0%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	FY2025	$44.1B to $44.5B	$44.556B	+$0.056B above high end	Beat
Adjusted EPS	FY2025	$22.60 to $22.86	$22.87	+$0.01 above high end	Beat
Adjusted Operating Margin	FY2025	22.7% to 22.8%	23.6%	+80 to +90 basis points above guidance	Beat
Organic Revenue Growth	FY2025	2% at midpoint	2%	in-line	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	FY2026	$46.3B to $47.2B	+4% to +6% YoY
Adjusted EPS	FY2026	$24.22 to $24.80	+6% to +8% YoY
Adjusted Operating Margin Expansion	FY2026	50 basis points	—
Net Interest Expense	FY2026	~$500M	—
Adjusted Income Tax Rate	FY2026	11.5%	—
Net Capital Expenditures	FY2026	$1.8B to $2.0B	—
Free Cash Flow	FY2026	$6.8B to $7.3B	—
Average Diluted Share Count	FY2026	370 to 375 million shares	—
2026 Organic Revenue Growth	Q1 FY2026	A couple of points lower than full year 2026	—

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Life Sciences Solutions	$2.946B	+13.1%
Analytical Instruments	$2.215B	+1.3%
Specialty Diagnostics	$1.22B	+5.5%
Laboratory Products and Biopharma Services	$6.379B	+7.5%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Organic Revenue Growth	3%
Life Sciences Solutions Segment Margin	35.5%
Analytical Instruments Segment Margin	26.3%
Specialty Diagnostics Segment Margin	26.6%
Laboratory Products and Biopharma Services Segment Margin	14.5%
Adjusted Operating Margin	23.6%
Capital Deployment	$16.5 billion in 2025, including $13 billion M&A and $3.6 billion shareholder returns
Full Year Organic Revenue Growth	2%

Management tone

Q1 macro defensiveness → Q2 explicit 2026–2027 valley framework → Q3 execution-driven raise → Q4 "position of strength" with quantified 2026 inflection.

For three quarters management framed 2025 as a "valley" and the 3–6% 2026–2027 organic band as an aspirational bridge that would be quantified when visibility returned. This quarter Casper opened with "we enter 2026 from a position of strength as the market leader serving attractive end markets" — and put a number on it: 3–4% organic, the lower half of the band. The shift from band-defending to number-committing is the most consequential tone change of the cycle, because it transforms a faith-based framework into a falsifiable guide.

The tariff narrative has fully inverted. In Q2 tariffs were a 140bps margin headwind that management was hoping to absorb; in Q3 tariffs delivered $0.11 of unexpected upside that management warned would not repeat. This quarter Casper said "we actively managed the company and our team responded with agility, effectively managing tariffs and the US policy dynamics to deliver a very strong year" — tariffs are no longer a headwind to disclose but a competitive advantage to claim. The receipt: FY adjusted operating margin expanded +10bps YoY to 22.7% despite >100bps of tariff and related FX headwinds absorbed in the year, per Williamson.

The AI story has compounded across three quarters. Q3 introduced ChatGPT Enterprise deployment and OpenAI embedding into product development; this quarter management announced an NVIDIA collaboration in analytical instruments and described AI as fused into the PPI business system itself: "we're also increasingly using artificial intelligence into PPI which will further enhance its impact across the organization." That is a different positioning than Q3 — PPI was the moat, AI is now the multiplier on the moat. Whether this shows up in margin algorithm acceleration beyond the guided +50bps is the open question.

The Clario announcement reframes M&A from "filtration/separation + Sanofi tuck-ins" (Q3) to platform expansion: "By adding Clario's high growth capabilities, over time, we will be able to deliver even deeper clinical insights for our customers and further accelerate the digital transformation of clinical research. This is an incredibly exciting opportunity." The $0.20–$0.25 of incremental partial-year EPS (with ~$0.45 of accretion in the first 12 months of ownership) and ~1pt of growth uplift to 7–9% total — if it closes mid-2026 — is what gets reported EPS growth back to the long-term 7%+ algorithm. Management is explicitly underwriting capital deployment as the bridge between the current ~3% organic run rate and the 7%+ destination.

The hedging is concentrated where it should be: tariffs as of today, Clario closing mid-2026, Q1 starting soft. Everything else is committed to with rare specificity for this management team.

Recurring themes management leaned on this quarter:

Organic growth acceleration from 2% (2025) to 3-4% (2026 guidance)Tariff/geopolitical resilience through active management and operational disciplineAI integration into PPI business system as competitive multiplierClinical research + digital endpoints (Clario) as transformational platformBioproduction momentum sustained across quartersShare gain momentum and market leadership reinforcement

Risks management surfaced:

Tariff policy uncertainty and potential additional levies impacting margins and FXChina market decline (mid-single digits full year 2025) and macro headwinds in U.S. and ChinaFX volatility (65 basis points of margin headwind in Q4 alone)Clario acquisition execution risk (closing expected mid-2026, not included in base guidance)Q1 2026 organic growth expected 2 points below full year due to selling days and pharma services phasing

Q&A highlights

Michael Riskin · Bank of America

What is underpinning the acceleration from 2% organic growth in 2025 to 3-4% guidance for 2026, and what gives confidence about this acceleration across end markets and customer groups?

Management assumes market conditions similar to 2025 (adjusted for ~1 point pandemic runoff, yielding roughly 3% baseline). The 3-4% range reflects absence of negatives allowing conditions to improve. No major market changes assumed to start the year. January customer meetings show optimism. Prior 3-6% framework for 2026-2027 combined remains intact with consistent forward assumptions. Management focusing on controlling destiny through 6-8% EPS growth without capital deployment embedded.

2025 adjusted organic growth was roughly 3% (excluding ~1 point pandemic runoff)2026 guidance of 3-4% organic growth assumes similar market conditions to 20256-8% EPS growth expected in 2026 without capital deployment embeddedPrior framework of 3-6% combined growth for 2026-2027 remains intact

Dan Arias · Stifel

Are improvements in pharma/biotech sentiment from MFN deals and government agreements actually translating into improved 2026 spending plans based on customer meetings?

Mid-single digit pharma growth in 2025 with pandemic headwinds. January healthcare conference and Europe meetings showed good pharma tone around government deals and pipeline confidence. Biotech funding is improving with positive customer sentiment, though lag exists between funding flows and spending. 'Trusted partner' positioning driving customer engagement beyond transactional relationships. Described detailed customer interactions showing deep collaboration on priorities and opportunities.

Mid-single digit organic growth in pharma in 2025Positive tone on pharma confidence navigating government agreementsBiotech funding showing signs of improvementTypical 6-month lag between biotech funding flows and spending

Jack Mann · Nefron Research

How is management feeling about pharma services supply-demand dynamics entering 2026 and what is reflected in guidance for that business?

Pharma services business executed very well with leading positions in sterile fill-finish and clinical trials logistics. Heightened demand relative to industry capacity in sterile fill-finish is driving growth. Sanofi New Jersey acquisition is capital project to expand capacity. Winning reshoring contracts from pharma customers. Demand profile is good and business will be nice contributor to long-term growth over next couple years.

Pharma services had strong year and will continue to grow over next couple yearsHeightened demand relative to industry capacity in sterile fill-finishSanofi New Jersey site acquisition supports capacity expansionWinning reshoring contracts for U.S. manufacturing

Matt LaRue · William Blair

How are ecosystem changes (manufacturing regionalization, AI in drug discovery) affecting customer preferences for outsourcing and specifically adoption of Xcelerator offering?

Xcelerator launched Q4 2024 with outstanding customer adoption and meaningful authorization wins for both clinical research and new pharma services contracts. Differentiates through accelerated drug development (reducing time/waste). Clinical research performed as expected with steady sequential progression and Q3 return to mid-single digit growth Q4. Collaborating with OpenAI on clinical research efficiency. AI in wet lab increases confidence in research quality, driving more experimentation not less. Seeing recovery in early research demand (bioscience reagents, basic R&D). Optimistic on intersection of AI and wet lab demand.

Xcelerator launched Q4 2024 with outstanding customer adoptionAuthorization wins ahead of revenue throughout clinical research yearClinical trials logistics and pharma services winning new total contracts from XceleratorMid-single digit organic growth in Q4 clinical research

Casey Woodring · J.P. Morgan

How did analytical instruments perform in Q4 relative to expectations across regions, and what are assumptions for U.S. academic and government growth in 2026 and timing of spending recovery after NIH budget finalization?

Analytical instruments had challenging Q4 comp with flat growth in quarter and modest full-year growth despite headwinds from academic/government funding pressures and China weakness. Strong pharma and biotech performance. Focus on innovation and breakthrough solutions is key driver. Applied AI to capabilities and announced NVIDIA collaboration. U.S. academic/government assumption for 2026 is similar cautious conditions to 2025. Expect customer caution to abate as year progresses. Likely flat-to-slightly-up NIH budget will be tailwind. Higher academic/government spending expected to drive movement higher in 3-4% range in coming years.

Q4 analytical instruments flat growth with tough compFull-year analytical instruments modest growthStrong performance with pharma and biotech customersPressure from academic/government funding and China weakness

Answers to last quarter's watch list

Did Q4 organic growth hold at or above 2% against the tougher comparison? Yes — Q4 organic was 3%, matching Q3 and well above the 2% floor. Analytical Instruments decelerated as warned (flat organic in Q4) but stayed non-negative. Status: Resolved positively

Did the $0.11 Q3 tariff benefit reverse or normalize in Q4? Management did not call out a comparable Q4 tariff tailwind, consistent with the Q3 framing. The cleanest evidence the tariff dynamic was managed cleanly: FY adjusted operating margin expanded +10bps YoY to 22.7% despite >100bps of tariff and related FX headwinds Williamson called out for the full year. Status: Resolved positively

Initial 2026 guidance — does the 3–6% framework get dollar-quantified, and is M&A dilution layered cleanly? Yes on both counts. The framework is now $46.3–$47.2B revenue (+4–6% reported, +3–4% organic) and $24.22–$24.80 adjusted EPS (+6–8%). The midpoint sits in the lower half of the 3–6% band. Clario is excluded from base guidance with separate disclosed 20–25c partial-year accretion (~$0.45 in the first 12 months of ownership) if it closes mid-2026, which is the cleanest M&A layering management has delivered in the cycle. Status: Resolved positively

China Q4 trajectory — did mid-single-digit decline sustain or narrow? Management referenced China as a full-year mid-single-digit decline (with Q4 specifically called out as low-single-digit decline) and continues to assume similar conditions into 2026 — i.e., stabilization, not recovery. The bridge assumption holds, but China is not contributing to the inflection. Status: Continue monitoring

Bioproduction bookings-to-revenue conversion in Life Sciences Solutions. Yes — Life Sciences Solutions delivered +4% organic in Q4 (LSS reported +13.1% with Filtration & Separation), with bioproduction explicitly called out as another quarter of excellent growth. Bookings outpacing revenue (Q3 commentary) has now translated into the organic line. Status: Resolved positively

FCF tracking the ~$7B FY guide. Missed. FY FCF closed at $6.34B vs. the ~$7B guide — roughly a 10% shortfall. Q4 FCF of $3.02B was strong but not enough to bridge the H1 gap. Williamson attributed the miss to temporary working capital impacts and timing of cash taxes, and the FY2026 FCF guide of $6.8–$7.3B implies only a modest recovery rather than a return to the prior trajectory. Status: Resolved negatively

What to watch into next quarter

Whether Q1-2026 organic growth comes in at the ~1% level CEO confirmed in Q&A without triggering a guidance walk-down on the full year — Q1 sets the credibility of the 3–4% FY commitment.

Whether Clario closes by mid-2026 as guided and whether the $0.20–$0.25 partial-year EPS accretion (~$0.45 over first 12 months of ownership) gets formally added to the FY guide on the Q2 call (taking total EPS growth to 7–9%) — this is the bridge between the current guide and the long-term 7%+ algorithm.

Adjusted operating margin progression toward the +50bps FY2026 expansion target — FY closed at 22.7%, so 2026 implies ~23.2% as the algorithm. Any quarter that delivers less than +50bps YoY puts the FY at risk given net interest expense (~$74M higher), tax rate (~110bps higher), and capex headwinds already absorbed in the EPS guide.

FCF recovery vs. the $6.8–$7.3B FY2026 guide — the 2025 miss to $6.34B vs. ~$7B target needs a clean trajectory after the working capital and cash-tax explanation. Watch the conversion ratio (FCF / adjusted net income) in Q1 specifically.

Analytical Instruments trajectory after the Q4 flat organic print — the segment needs to re-accelerate as academic/government caution abates and NIH budget clarity emerges; a stall here breaks the FY 3–4% organic build.

China commentary — management is assuming similar conditions to 2025 (mid-single-digit FY decline). Any return toward Q2's high-single-digit decline pace breaks the bridge.

Sources

Thermo Fisher Q4 2025 Earnings 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000012/q42025earnings8kex99_1.htm
Thermo Fisher Q4 2025 earnings call commentary (Mark Casper, Stephen Williamson, and analyst Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.